Comments
Cadila Healthcare today said group firm Zydus Cadila has received final approval from the US health regulator to market Candesartan Cilexetil and Hydrochlorothiazide tablets formulations used in treating high blood pressure.
The approval by the US Food and Drug Administration (USFDA) is for multiple Candesartan Cilexetil and hydrochlorothiazide tablets of 16 mg/12.5 mg, 32 mg/12.5 mg and 32 mg/25 mg, Cadila Healthcare said in a BSE filing.
The drug is used to treat high blood pressure. Lowering blood pressure helps prevent strokes, heart attacks and kidney problems, it added.
“It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad,” the filing said.
The group has now more than 175 approvals and has so far filed 310 ANDAs since the commencement of the filing process in FY2003-04, it said.
Shares of Cadila Healthcare were trading at Rs 442 apiece in afternoon trade, up 0.15 per cent from the previous close on BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.